|
Gene: SYNRG |
Gene summary for SYNRG |
Gene summary. |
Gene information | Species | Human | Gene symbol | SYNRG | Gene ID | 11276 |
Gene name | synergin gamma | |
Gene Alias | AP1GBP1 | |
Cytomap | 17q12 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q9UMZ2 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
11276 | SYNRG | GSM4909292 | Human | Breast | IDC | 4.09e-02 | 5.21e-01 | 0.1236 |
11276 | SYNRG | GSM4909317 | Human | Breast | IDC | 1.47e-02 | 2.41e-01 | 0.1355 |
11276 | SYNRG | GSM4909319 | Human | Breast | IDC | 2.19e-02 | -9.67e-03 | 0.1563 |
11276 | SYNRG | NCCBC14 | Human | Breast | DCIS | 2.20e-15 | 6.87e-01 | 0.2021 |
11276 | SYNRG | DCIS2 | Human | Breast | DCIS | 5.65e-38 | 1.94e-01 | 0.0085 |
11276 | SYNRG | LZE4T | Human | Esophagus | ESCC | 8.93e-07 | 3.20e-01 | 0.0811 |
11276 | SYNRG | LZE7T | Human | Esophagus | ESCC | 5.05e-13 | 6.08e-01 | 0.0667 |
11276 | SYNRG | LZE8T | Human | Esophagus | ESCC | 4.99e-04 | 1.92e-01 | 0.067 |
11276 | SYNRG | LZE20T | Human | Esophagus | ESCC | 4.68e-07 | 1.99e-01 | 0.0662 |
11276 | SYNRG | LZE22T | Human | Esophagus | ESCC | 3.55e-02 | 2.28e-01 | 0.068 |
11276 | SYNRG | LZE24T | Human | Esophagus | ESCC | 2.26e-19 | 5.41e-01 | 0.0596 |
11276 | SYNRG | LZE21T | Human | Esophagus | ESCC | 8.21e-05 | 2.92e-01 | 0.0655 |
11276 | SYNRG | P1T-E | Human | Esophagus | ESCC | 1.20e-12 | 4.89e-01 | 0.0875 |
11276 | SYNRG | P2T-E | Human | Esophagus | ESCC | 4.19e-30 | 3.86e-01 | 0.1177 |
11276 | SYNRG | P4T-E | Human | Esophagus | ESCC | 1.23e-16 | 3.91e-01 | 0.1323 |
11276 | SYNRG | P5T-E | Human | Esophagus | ESCC | 2.53e-14 | 1.94e-01 | 0.1327 |
11276 | SYNRG | P8T-E | Human | Esophagus | ESCC | 2.29e-22 | 3.75e-01 | 0.0889 |
11276 | SYNRG | P9T-E | Human | Esophagus | ESCC | 2.65e-10 | 1.82e-01 | 0.1131 |
11276 | SYNRG | P10T-E | Human | Esophagus | ESCC | 1.96e-13 | 2.08e-01 | 0.116 |
11276 | SYNRG | P11T-E | Human | Esophagus | ESCC | 3.50e-14 | 4.98e-01 | 0.1426 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SYNRG | SNV | Missense_Mutation | novel | c.2825N>T | p.Thr942Ile | p.T942I | Q9UMZ2 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.475) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SYNRG | SNV | Missense_Mutation | novel | c.3383N>T | p.Ala1128Val | p.A1128V | Q9UMZ2 | protein_coding | tolerated(0.09) | probably_damaging(0.997) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
SYNRG | SNV | Missense_Mutation | novel | c.2747G>T | p.Gly916Val | p.G916V | Q9UMZ2 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.945) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
SYNRG | SNV | Missense_Mutation | novel | c.973C>A | p.Leu325Met | p.L325M | Q9UMZ2 | protein_coding | deleterious(0.04) | probably_damaging(0.999) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
SYNRG | SNV | Missense_Mutation | novel | c.686N>T | p.Ala229Val | p.A229V | Q9UMZ2 | protein_coding | tolerated(0.08) | benign(0.185) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
SYNRG | SNV | Missense_Mutation | rs763045470 | c.3904N>A | p.Glu1302Lys | p.E1302K | Q9UMZ2 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SYNRG | SNV | Missense_Mutation | novel | c.3536G>T | p.Arg1179Met | p.R1179M | Q9UMZ2 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
SYNRG | SNV | Missense_Mutation | novel | c.3383C>T | p.Ala1128Val | p.A1128V | Q9UMZ2 | protein_coding | tolerated(0.09) | probably_damaging(0.997) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
SYNRG | SNV | Missense_Mutation | novel | c.1115T>C | p.Met372Thr | p.M372T | Q9UMZ2 | protein_coding | deleterious(0.02) | benign(0.075) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
SYNRG | SNV | Missense_Mutation | novel | c.715C>T | p.Pro239Ser | p.P239S | Q9UMZ2 | protein_coding | tolerated(0.14) | benign(0.405) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |